RxSight (RXST) Cash & Current Investments (2020 - 2026)

RxSight (RXST) has 7 years of Cash & Current Investments data on file, last reported at $217.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 5.0% year-over-year to $217.9 million; the trailing twelve-month figure through Mar 2026 stood at $217.9 million (down 5.0% YoY), and the FY2025 full-year result was $228.1 million, down 50.16% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $217.9 million, down from $228.1 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $457.7 million in Q4 2024 and bottomed at $131.9 million in Q3 2023.
• The 5-year median for Cash & Current Investments is $229.3 million (2025), against an average of $247.3 million.
• The widest annual swing landed in 2022, when Cash & Current Investments jumped 189.03%; it then tumbled 50.16% in 2025.
• A 5-year view of Cash & Current Investments shows it stood at $196.8 million in 2022, then increased by 21.65% to $239.5 million in 2023, then soared by 91.15% to $457.7 million in 2024, then sank by 50.16% to $228.1 million in 2025, then decreased by 4.49% to $217.9 million in 2026.
• The last three Cash & Current Investments figures came in at $217.9 million (Q1 2026), $228.1 million (Q4 2025), and $227.5 million (Q3 2025), per Business Quant data.

Peer Comparison